The Effect of Pimozide and Apomorphine on Dopamine-Induced Renin Release, Tissue Renin Content, and 3\u275\u27-Adenosine Monophosphate Levels in Rat Venal Cortical Slices by Rao, Visalakshi
Loyola University Chicago
Loyola eCommons
Master's Theses Theses and Dissertations
1980
The Effect of Pimozide and Apomorphine on
Dopamine-Induced Renin Release, Tissue Renin
Content, and 3'5'-Adenosine Monophosphate
Levels in Rat Venal Cortical Slices
Visalakshi Rao
Loyola University Chicago
This Thesis is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons. It has been accepted for inclusion in
Master's Theses by an authorized administrator of Loyola eCommons. For more information, please contact ecommons@luc.edu.
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
Copyright © 1980 Visalakshi Rao
Recommended Citation
Rao, Visalakshi, "The Effect of Pimozide and Apomorphine on Dopamine-Induced Renin Release, Tissue Renin Content, and 3'5'-
Adenosine Monophosphate Levels in Rat Venal Cortical Slices" (1980). Master's Theses. Paper 3106.
http://ecommons.luc.edu/luc_theses/3106
THE EFFECT OF PIMOZIDE AND APOMORPHINE 
ON DOPAMINE-INDUCED RENIN RELEASE, 
TISSUE RENIN CONTENT, AND 
3'5'-ADENOSINE MONOPHOSPHATE LEVELS IN 
RAT RENAL CORTICAL SLICES 
by 
Visalakshi Rao 
A Thesis Submitted to the Faculty of the Graduate School 
of Loyola University of Chicago in Partial Fulfillment 
of the Requirements for the Degree of 
Master of Science 
April 
1980 
ACKNOWLEDGMENTS 
I would like to express my heartfelt thanks to Dr. G.A. 
Lopez for his encouragement, advice and guidance during the 
course of my graduate research. Thanks are also due to the 
members of my Committee, Drs. A.J. Rotermund and J.J. Peluso 
for their valuable advice. My fellow graduate students, 
Suzanne M. Mottel and Brett Sheppard are also thanked for 
their support and friendship. My sincere ~ppreciation is 
extended to Dr. N.J. Dun, Department of Pharmacology, Stritch 
School of Medicine of Loyola University for the donation of 
apomorphine, Dr. R. Gallo, Department of Physiology, Univer-
sity of California for supplying pimozide and Dr. A. Krause, 
Argonne National Labs for the use of Hewlett-Packard Program-
mable calculator. 
Finally I would like to thank the members of my family 
for their love and understanding. For the technical assis-
tance in the preparation of this manuscript, I would like to 
thank my sister, Usha. 
ii 
VITA 
The author, Visalakshi Rao, is the daughter of Yedavalli 
Shyamsunder Rao and Kameswari (Veluri) Rao. She was born on 
January 2, 1957 in Secunderabad, India. 
Her elementary education was obtained in the public and 
parochial schools of Chicago, Illinois and the public schools 
of Ontario, Canada. She graduated from Oak Park-River Forest 
High School Oak Park, Illinois, in June 1973. 
In September 1973, she entered the University of Illi-
nois at Chicago Circle ~d graduated in March 1977 with a 
Bachelor of Science degree in Biology. 
In September 1978, she entered the Masters program at 
Loyola University of Chicago and was awarded a teaching as-
sistantship in September 1979. 
She is the author or co-author of a number of research 
papers: 
Rao, v., Evidence for a Dopamine-Receptor Mediated 
Inhibition of Renin Release. Sigma Xi Graduate 
Student Research Forum, Loyola University Stritch 
School of Medicine, 1980. 
Rao, v., s. Mottel, B. Sheppard, G.A. Lopez, Evidence 
for a Dopamine-Receptor Mediated Inhibition of Ren-
in Release, Illinois State Academy of Science, 
1980. 
Lopez, G.A., s. Mottel, v. Rao, B. Sheppard, Further 
Evidence for Cyclic AMP Mediation of the Stimula-
iii 
tory Effect of Dopamine on Renin Release In Vitro, 
Fed. Proc., 39: 827, 1980. --
Lopez, G.A., s. Mottel, v. Rao, B. Sheppard, Evidence 
for a Dual Regulatory Mechanism Mediating the Ef-
fect of Dopamine on Renin Release in the Sodium 
Deficient Rat, Proc. Soc. Exp. Biol. Med., (sub-
mitted for publication). 
Lopez, G.A., v. Rao, s. Mottel, and B. Sheppard, Stimu-
lation of Renin Release by Pimozide Via a General-
ized Membrane Effect Involving Inactivation of 
Adenylate Cyclase in Rat Kidney Slices, Life Sci-
ences (submitted for publication). 
iv 
TABLE OF CONTENTS 
Acknowledgments • • • • • • • • • • • • • • • • • • • • • ii 
Vita • • • • • • • • • • • • • • • • • • • • • • • • • .iii 
List of Figures • • • • • • • • • • • • • • • • • • • • .vii 
Chapter 
I. Introduction • • • • • • • • • • • • • • • • • • 1 
II. Literature Review 
A) Renin-Angiotensin-Aldosterone 
Regulation of Electrolyte and 
Blood Pressure Homeostasis • • • • • • • • • 4 
B) Control of Renin Secretion 
1) Intrarenal Control 
a) Afferent Arteriole Baroreceptor 
Control of Renin Release • • • • • • 5 
b) Macula Densa Control of 
Renin Release , • • • • • • • • • • • 6 
2) Humoral Factors • • • • • • • • • • • • 7 
3) Central Nervous Control of 
Renin Release • • • • • • • • • • • • • 9 
4) Peripheral Sympathetic Neural 
Control of Renin Release 
a) Effects of Renal Nerve 
StLmulation and Renal 
Denervation • • • • • • • • • • • • 11 
b) Adrenergic Receptor 
Mediation of Renin 
Secretion • • • • • • • • • • • • • 12 
c) The Dopamine Vascular 
Receptor and Dopaminergic 
Control of Renin Release • • • • • • 13 
III. Materials and Methods 
A) Tissue Cyclic AMP Extraction and 
Measurement of its Content • • • • • • • • • 20 
B) Purification of Tissue Renin • • • • • • • • 21 
C) Angiotensin I Generation and 
Measurement • • • • • • • • • • • • • • • • 21 
IV. Results • • • • • • e • • • • • • • • • • • • • 24 
v. Discussion • • • • • • • • 
References • • • • • • • • • • • • 
• • • • • • 
• • • • • • 
• • 
• • 
• • 
• • 
• 
• 
39 
45 
LIST OF FIGURES 
1) Resting renin release rate and tissue cyclic AMP levels 
in renal cortical slices from sodium deficient rats. 
2) The effect of dopamine administration on renin release, 
tissue cyclic AMP and tissue renin content. 
3) Changes in renin release, tissue cyclic AMP content and 
tissue renin content in response to apomorphine added 
separately or together with dopamine. 
4) Renin release, tissue cyclic AMP content and tissue renin 
content responses to dopamine added alone or together 
with pimozide during a 60 min incubation period. 
5) Effect of pimozide administration on renin release, tis-
sue cyclic AMP content and tissue renin content. 
6) Changes in renin release, tissue cyclic AMP content, and 
tissue renin content in response to dopamine added alone 
or in conjunction with theophylline, d-butaclamol, or 
apomorphine. 
vii 
CHAPTER I 
INTRODUCTION 
In vitro studies in our laboratory (1,2) and elsewhere 
(3,4) have shown that dopamine can directly stimulate renin 
release from the mammalian renal juxtaglomerular cells and 
that this effect appears to be mediated by a beta-adrenergic 
receptor mechanism involving increases in tissue cyclic AMP 
levels (1,2). We have also evaluated the possibility that 
dopamine-specific receptors may participate in the regula-
tion of renin secretion {1,2). In these studies, the dop-
amine-receptor blocking agent, pimozide, significantly sti-
mulated renin secretion from renal cortical slices of sodium 
deficient rats. This marked increase in renin secretion 
occured whether or not dopamine was added in conjunction with 
this agent, suggesting that the stimulatory effect is due to 
pimozide itself. Furthermore, the observed increase in renin 
secretion in response to various doses of pimozide was 
coupled with a significant decrease in tissue cyclic AMP 
content after a one hour incubation period. These data sug-
gest an inhibitory action of dopamine or renin release which 
is prevented by administration of pimozide. Conversely, 
these results could reflect a generalized effect of pimozide 
1 
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on the juxtaglomerular cell membrane resulting in uncontrol-
led release of pre-formed renin. Clearly, further studies 
are required in order to fully evaluate the type of mechan-
ism by which pimozide itself influences renin secretion, and 
to further examine the possibility that dopaminergic recep-
tors may participate in the regulation of renin release. 
~ vitro renal tissue preparations are particularly use-
ful in the examination of specific factors which may directly 
affect renin release since they effectively eliminate the 
action of other factors known to influence renin release in 
the live animal. Furthermore, ~ ~ (5-8) and in vitro 
studies {1,2,9-11) have shown that both renin secretion and 
the renin secretory responses to sympathetic stimuli, are 
potentiated by dietary sodium deprivation. Thus, a renal 
cortical slice preparation from sodium deficient rats which 
maximizes juxtaglomerular cell responsiveness, is an effec-
tive tool for the evaluation of the mechanisms by which iso-
lated factors regulate renin secretion. 
The present study utilizes a hypersensitive renal cor-
tical slice system from the sodium deficient rat to: 1) 
determine if the stimulatory effect of dopamine on renin se-
cretion involves the release of pre-formed renin and/or ~ 
~ synthesis of renin, by examining both secretory and 
tissue renin content changes in response to dopamine admin-
istration at various time intervals; 2) further evaluate 
the possible role of dopaminergic receptors in the regula• 
tion of renin release by utilizing the dopamine-receptor 
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agonist, apomorphine; 3) provide additional evidence for a 
possible mechanism by which pimozide itself may affect renin 
release by examining the changes in tissue renin content, 
tissue cyclic AMP levels, and renin secretion rate with time, 
in response to administration of this agent to the renal cor-
tical slice system and; 4) further investigate the role of 
cyclic AMP as an intracellular mediator by determining if 
tissue content responses of this nucleotide are coupled with 
changes in tissue renin content and renin release. 
Portions of these data have been reported in prelimin-
ary form (12). 
CHAPTER II 
LITERATURE REVIEW 
A. Renin-Angiotensin-Aldosterone Regulation of Electrolyte 
and Blood Pressure Homeostasis 
Renin, a glycoprotein (13) synthesized in the juxtaglo-
merular cells of the kidney, is normally secreted into the 
systemic circulation where it cleaves a hepatic alpha2-glo-
bulin angiotensinogen (renin substrate) to form the decapep-
tide angiotensin I (13). Angiotensin I is further split by 
the action of a circulating converting enzyme to yield the 
powerful vasoconstricting agent angiotensin II (13). Angio-
tensinase enzymes present in the systemic circulation in 
turn inactivate angiotensin II to produce metabolic by-pro-
ducts which possess little or no vasoconstrictor activity 
and, are normally excreted in the urine (13). In addition 
to its metabolic fragment angiotensin III, can exert an in-
direct regulatory effect on blood volume. Both angiotensin 
II and angiotensin III infusions stimulate synthesis and se-
cretion of aldosterone and antidiuretic hormone (ADH), there-
by effecting electrolyte and blood volume homeostasis (14-
4 
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16). Thus, renin, through its effect on angiotensin II and 
aldosterone production, is an important factor in the main-
tenance of electrolyte, blood pressure and blood volume ho-
meostasis. 
B. Control of Renin Secretion 
It is well established that renin release in the live 
animal, is under the simultaneous influence of a variety of 
factors. These factors include: 1) intrarenal receptors, 
such as the afferent arteriole baroreceptor and the macula 
densa natrioreceptor; 2) humoral factors such as ADH, angio-
tensin II, estrogen, and intrarenal prostaglandins; 3) cen-
tral nervous system pathways originating in the vasomotor 
centers of the medulla oblongata and the hypothalamus; and 
4) peripheral sympathetic neural mechanisms which are medi-
ated by the renal nerves and circulating catecholamines from 
the adrenal medulla. 
1. Intrarenal Receptors 
a. Afferent Arteriole Baroreceptor Control of Renin 
Release 
The renin-secreting juxtaglomerular cells are modified 
smooth muscle cells and as such are sensitive to stretch. 
Tobian (17) and Skinner (18) first proposed the existence of 
a renal perfusion pressure, asd a number of subsequent stu-
dies have confirmed their findings by demonstrating that al-
6 
terations in renal blood flow and perfusion pressure can mod-
ify renin release. Utilizing the non-filtering, denervated 
kidney in the dog, Blaine and co-workers (19,20) have shown 
that the influence of the baroreceptor mechanism can be fully 
exerted in the absence of a functional macula densa and the 
renal nerves, suggesting that this pathway can operate inde-
pendently of the other factors which affect renin secretion. 
Conversely, infusion of the smooth muscle relaxing agent, 
papaverine into the renal artery of the non-filtering dog 
kidney (21), have been shown to block the secretory responses 
to hemorrhage, further supporting the existence of a vascular 
baroreceptor mechanism, participating in the regulation of 
renin release. 
b. Macula Densa Control of Renin Release 
The close anatomical association between the macula 
densa cells of the distal convoluted tubule and the juxtaglo-
merular cells of the renal afferent arteriole, has led to 
the hypothesis that renin release may also be modified by 
the electrolyte composition of the filtrate in the distal 
tubule. However, the mechanism by which these changes ul-
timately affect renin release is still under debate. Studies 
by Vander and Miller (22) have suggested that a decreased 
sodium load to the macula densa area is the main stimulus 
leading to renin release. However, micropuncture studies by 
Thurau and associates (23) have shown that it is an increas-
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ed delivery of sodium to the macula densa area which is re-
sponsible for the observed effects on renin release. Studies 
by Nash et. al. (24) and Humphrey et. al. (25) have supported 
this later view. These data, therefore, can be interpreted 
as being suggestive of participation of the macula densa 
mechanism primarily in those instances in which renin release 
is to be inhibited. Alternatively, Barajas (26) has pro-
posed that macula densa influence on renin release is depen-
dent on the degree of distal tubular and afferent arteriolar 
contact and that contact increases with increasing tubular 
sodium concentration. Recently, some studies have proposed 
that distal tubular chloride load rather than sodium load 
may be the stimulus for triggering the macula densa-dependent 
effect on renin secretion (27,28,110,111). 
2. Humoral Factors 
A large number of circulating factors are known to in-
fluence renin secretion. Most important among these angio-
tensin II and ADH, and to a lesser degree, ovarian estrogens 
and adrenal corticoids. 
Infusions of angiotensin II into the renal artery of 
dogs have been shown to inhibit renin release (29-32), pos-
sibly a direct negative feedback effect on the juxtaglomeru-
lar cells or, indirectly through its effect on vascular con-
tractility (31,32). Blair-West and associates (31) have 
demonstrated that chronic intravenous infusion of angiotensin 
8 
II prevents the rise in plasma renin activity associated with 
sodium depletion. Shade et •. al. (32) have extended these 
findings by showing that the inhibitory effect of angiotensin 
II on renin secretion is not only seen in the non-filtering 
kidney, but it also appears to be independent of renal blood 
flow and arterial pressure changes, thus supporting the view 
of a direct feedback effect of this agent on renin release. 
This concept has received added support by investigators uti-
lizing ~ vitro kidney slice systems (10,33) or the isolated, 
perfused rat kidney (34). 
ADH has also been postulated to exert an inhibitory in-
fluence on renin secretion {30,32,35). Tagawa and associ-
ates {36) have confirmed these observations by showing that 
physiological increases in ADH cause significant decreases 
in renin secretion in the unanesthetized sodium-deprived dog. 
However, the mechanisms mediating this inhibitory control of 
renin release by ADH remains unclear. 
The effects of ovarian estrogens and adrenal steroids 
on renin secretion have also been investigated. Oral estro-
genic contraceptives are known to cause variable increases 
in plasma renin activity {37) perhaps by their stimulatory 
action of hepatic production of renin substrate. Conversely, 
adrenal glucocortocoids may influence renin release through 
their actions of renal hemodynamics and glomerular filtra-
tion rate (38). Aldosterone, however, appears to have no 
direct influence on renin secretion but it may indirectly 
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affect it by its known action on sodium reabsorption (39). 
Recent studies in a number of laboratories have pres.ent-
ed evidence supporting the view that prostaglandins partic~­
pate in the control of renin release in normal and patholo-
gical states. Treatment of malignant hypertension with·the 
cyclooxygenase inhibitor, indomethacin, has been shown to· 
supress plasma renin activity (40). Administration of ara-
chidonic acid, a prostaglandin precursor, stimulates renin 
release in renal cortical slices of the rabbit (41). PGI2 
has been found to be present in large concentrations in the 
renal cortex and to be capable of stimulating renin secre-
tion in both the intact kidney and in renal cortical slices 
(41,42). However, the mechanism involved in the action of 
prostaglandins remains to be determined. 
3. Central Nervous Control of Renin Release 
It is now clear that a central nervous mechanism parti-
cipates in the peripheral regulation of renin release. Sti-
mulation of the pons results in dramatic increases in the 
rate of renin release in the intact kidney (43-44). Ueda 
et. al. (45) have observed similar increases following mesen-
cephalic stimulation. Zehr and Feigel (46) have presented 
data suggesting the existence of a central inhibitory compo-
nent as well. In their studies, they found that stimulation 
of the anterior hypothalamus resulted in the suppression of 
plasma renin activity in the unanesthetized dog. These 
10 
results are consistent with the antagonistic roles these 
areas playin the regulation of behavior and circulation (47). 
In addition to the direct regulatory action of angio-
tensin II on renin secretion, recent evidence indicates that 
it also has a central regulatory role. Infusions of this 
agent into the third cerebral ventricle, are followed by a 
decrease in plasma renin activity (16,48). It is not known 
whether this effect may be exerted by angiotensin II genera-
ted locally in the brain or alternatively, by systemic angio-
tensin II which crosses the blood brain barrier. Regardless, 
the possible existence of a functional brain renin angioten-
sin system is currently the subject of much controversy. 
Philips et. al. (49) have shown that in addition to angio-
tensin II, other components of the system including renin, 
angiotensinogen, and converting enzyme are also present in 
brain tissue, thus supporting the existence of a central 
renin-angiotensin system. Conversely, Day and Reid (50) have 
suggested that brain •renin" is instead the lysosomal enzyme 
cathepsin D. Additionally, they indicate that the optimum 
pH for this so-called brain "renin" enzyme is outside the 
physiological range, and that the concentrations of the 
other components of the system are too small to be of func-
tional significance. 
4. Peripheral Sympathetic Neural Control of Renin Release 
Numerous electron microscopic (51-53) and histo-chemi-
11 
cal flourometric studies (54,55), have demonstrated the pre-
sence of a large network of nerve terminals in close associ-
ation with the renal afferent and efferent arterioles and 
the juxtaglomerular cells. These studies have also demon-
strated that these nerve terminals are primarily sympathetic 
in nature. These observations have led to the postulation 
that the renal sympathetic nerves may play an important role 
in the homeostatic regulation of renin secretion. 
a. Effects of Renal Nerve Stimulation and Renal Dener-
vation 
It is generally accepted that the sympathetic nervous 
system can influence renin release by both circulating cate-
cholamines from the adrenal medulla and by norepinephrine 
secreted by renal sympathetic nerve terminals (39,56). The 
effect of circulating epinephrine and norepinephrine on ren-
in secretion may be indirectly mediated through their actions 
on the afferent arteriole baroreceptors, or the macula densa 
natrioceptors. On the other hand, norepinephrine released 
by renal sympathetic nerve terminals may directly stimulate 
renin release through an interaction with specific receptors 
located on the juxtaglomerular cell membrane (10,13). 
Evidence for a direct sympathetic effect which is inde-
pendent of vascular and macula densa influences, has been 
gathered from a number of studies. Johnson et. al. (57} 
showed that electrical stimulation of the renal nerves caused 
12 
an increase in renin release from the non-filtering dog kid-
ney treated with papaverine to inactivate baroreceptor re-
sponses. Similarly, increases in renin release produced by 
the stimulation of the vasomotor area of the cat brain are 
abolished by renal denervation or treatment with the beta-
adrenergic blocker, propranolol (44). Other studies have ad-
ditionally demonstrated that renal nerve stimulation can di-
rectly affect renin release in the absence of other factors 
{58-60). 
Data generated from studies which have utilized the de-
nervated kidney have largely confirmed these findings. Passe 
et. al. (43) found that the increase in renin release associ-
ated with stimulation of the medulla oblongata, was abolished 
by renal denervation. Denervation has also been shown to 
prevent the effects of postural changes and furosemide infu-
sion on renin secretion (61). Sympathetic effects on renin 
release are also blocked by administration of propranolol 
(44), by ganglionic blockade or by local anesthesia (30). 
b. Adrenergic Receptor Mediation of Renin Secretion 
Numerous in vivo and in vitro studies have shown that 
catecholamine administration results in an increase in renin 
release (1,2,6,9,10,58,62-67). Experiments by Otsuka et. al. 
(68) in the dog indicate that the marked increase in renin 
release caused by insulin-induced hypoglycemia, can be abol-
ished by adrenal denervation and restored by catecholamine 
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infusion. Thus, these data are indicative of the direct ef-
fect of catecholamines on the renin secreting juxtaglomeru-
lar cells. 
The stLmulatory effect of catecholamines on renin se-
cretion has been postulated to be mediated by a beta-adrener-
gic receptor-mechanism (1,2,9,10,69-72), involving intracel-
lular generation of cyclic AMP (1,2,9,10,70-73). 
Alternatively, Vandogen et. al. (74), Nally et. al. 
(70) , and Pettinger (75) , have evaluated the role of alpha-
adrenergic receptors in the control of renin secretion. 
Their data show that stimulation of renal alpha-adrenergic 
receptors results in a marked inhibition of renin secretion, 
which can be prevented by the addition of alpha-blocking 
agents. Moreover, this inhibitory effect on renin release 
produced by alpha-adrenergic receptor activation has been 
shown to be coupled with significant decreases in the cyclic 
AMP content of the renal tissue (9,10,76). 
c. The Dopamine Vascular Receptor and Oopaminergic 
Control of Renin Release 
It has been amply demonstrated that dopamine is an ob-
ligatory precursor of norepinephrine in the central nervous 
system and in peripheral sympathetic nerve terminals (77). 
It is also known that dopamine is an important central 
neurotransmitter (78) and its presence has been reported in 
renal tissue (79). In view of these findings, considerable 
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interest has arisen in recent years in regard to the possibi-
lity that this catecholamine precursor may participate in 
the regulation of renin secretion. This has been further 
strengthened by the findings of a number of investigators 
pointing to the existence of a renal dopaminergic receptor 
which may mediate renal vascular dynamics (80~89). 
McDonald et. al. (80,81), have reported that intraven-
ous infusion of dopamine in human subjects, results in mark-
ed reduction in renal arterial resistance coupled with a 
significant increase in renal plasma flow and sodium excre-
tion. McNay et. al. {82), have observed a similar effect in 
the anesthetized dog. Since alpha- and beta-blocking agents 
did not alter these responses, they suggested that dopamine 
may exert its effect by an alternate receptor mechanism, 
possibly one that is dopamine-specific. The experiments of 
Yeh and co-workers (83), in which intrarenal injections of 
the dopamine-receptor blocker, haloperidol, attenuated the 
renal vasodilating effect of dopamine provided added support 
for the existence of a dopamine renal vascular receptor. 
Similar results have been obtained using additional dopamine-
receptor blockers such as chloropromazine (84), and bulbo-
capnine (85,86). Furthermore, the dopamine-receptor agonist 
apomorphine and the N-methyl dopamine analog epinine, have 
been shown to cause dopamine-like effects on renal vasodila-
tion (87) • 
Nakajima and collegues (88,89) have extended these 
15 
findings by suggesting that the action of this dopamine vas-
cular receptor may depend on the activation of an adenylate 
cyclase system. In their studies, addition of dopamine to a 
rat kidney particulate preparation resulted in a significant 
increase in the cyclic AMP content of the medium, which was 
unaffected by alpha- (phentolamine) or beta- (propranolol) 
blockade. Conversely, spiroperidol an effective dopamine-
receptor antagonist, blocked this stimulatory effect while 
the dopamine-receptor agonist apomorphine potentiated it. A 
subsequent study by the same investigators {89) confirmed 
their original observations and further demonstrated that, 
the increased cyclic nucleotide levels produced by addition 
of the phosphodiesterase inhibitor theophylline, were effec-
tively blocked by spiroperidol. Taken together, these find-
ings support the existence of a dopamine-specific, adenylate-
sensitive, vascular receptor in the kidney. This is consis-
tent with other evidence suggesting the presence of similar 
cyclic AMP-mediated dopamine receptors in the brain and re-
tina (90-92). In view of the previously discussed data re-
garding the role of dopamine in the regulation of renal vas-
cular dynamics, a number of studies are presently being di-
rected toward determining whether dopamine may have a direct 
effect on the juxtaglomerular cells to increase renin secre-
tion, and thus indirectly regulate electrolyte, blood volume, 
and blood pressure homeostasis. 
Working ~ ~~ Ayers and collegues (62) have shown 
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that dopamine administration results in a marked increase in 
renin release. Bell and Lang (93) have also demonstrated 
that dopamine can stimulate renin secretion and that this 
effect is blocked by the dopamine-receptor antagonist, ergo-
metrine. Wilcox et. al. (65), as well as Imbs and collegues 
{94,95), have confirmed these observations. 
On the other hand, some studies have provided contradic-
tory evidence. Cuche et. al. (96) found an inverse rela-
tionship between urinary dopamine and plasma renin activity, 
as a result of postural changes from the supine to the up-
right position. Since plasma renin activity increased while 
urinary dopamine decreased, they suggested a possible inhi-
bitory role for dopamine on renin release, mediated by changes 
in renal plasma flow or sodium load to the macula densa. 
Chokshi and associates (97), have supported this concept by 
showing that renal artery infusion of dopamine causes an in-
crease in renal plasma flow and a simultaneous decrease in 
renin secretion. 
In vitro studies generally supported the view of a di-
rect action of dopamine on renin release. Henry and co-work-
ers (3) have demonstrated in a rat renal cortical prepara-
tion, that administration of dopamine doses of 10-7M or 
greater results in significant increases in renin secretion. 
They also found that alpha-receptor blockade (phentolamine}, 
dopamine-receptor blockade (haloperidol) , or addition of co-
caine (a catecholamine re-uptake inhibitor}, did not alter 
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the stimulatory effect of dopamine, but that propranolol ad-
ministration effectively prevented it. They concluded that 
renin release may be partially regulated by a beta-adrener-
gic mechanism, and that dopamine-specific receptors may not 
participate in this regulation. Their findings have been 
supported by Quesada et. al. (4). SLmilar in vitro studies 
in our laboratory (1,2) have confirmed Henry's and Quesada's 
observations in regard to the stimulatory effect of dopamine 
on renin release and the inhibition of this effect by propra-
nolol. However, we have further extended their observations 
by demonstrating that both, the stimulatory effect on release 
and the blockade of this effect by propranolol, are coupled 
with corresponding changes in the cyclic AMP content of the 
sliced tissue. These data strongly support the view that 
the action of dopamine on renin secretion, similar to that 
exerted by norepinephrine, is mediated by the activation of 
an adenylate cyclase receptor complex in the membrane of the 
juxtaglomerular cells. Also, since the data regarding the 
possible participation of dopamine-specific receptors is 
controversial at best, it is clear that further studies de-
signed to investigate this possibility are in order. 
CHAPTER III 
MATERIALS AND METHODS 
Male, Sprague-Dawley rats (Sprague-Dawley co.) with in-
itial weights of 210 ± lOg, were fed a sodium deficient diet 
(Teklad Test Diet Co.) providing less than 0.02mEq of sodium 
per day for 1.5 to 2.5 weeks. Male animals were chosen to 
eliminate the influence of cyclic estrogenic variations, in 
view of reports that circulating estrogens can exert effect 
on renin release (37). They were kept in a temperature-con-
trolled room, two animals per cage and had unlimited access 
to distilled-deionized water. At the end of the dietary in-
take period, the animals were sacrificed by decapitation and 
their kidneys rapidly excised, gassed for 30 sec with 95% o2 
- 5% co2 prior to and after decapsulation, and placed in 
Robinson's buffer medium (98) at 4°C. Renal cortical slices 
approximately 0.3mm thick were prepared using a Stadie-Riggs 
microtome (A. Thomas Co.). Each cortical slice was further 
divided into several portions according to the number of 
treatments, and randomly assigned to separate incubating 
vessels containing 2.5 ml of Robinson's buffer. This pro-
cedure was repeated using other areas of the renal cortex 
until each vessel contained 50 ± 30mg of cortical tissue. 
18 
19 
This random distribution of sliced tissue ensured that all 
incubating vessels contained a homogeneous cell population 
from each cortical area, and thus allowed one of each group 
to be used as a common untreated control for each group of 
treatments. The tissue was then pre-incubated for 15 min at 
37°C in a shaking Dubnoff Metabolic Incubator (Precision 
Scientific), in an atmosphere saturated with 95% o2 - 5% co2 • 
The pre-incubated slices were subsequently transferred to 
corresponding incubating vessels containing 2.5 ml of Robin-
son's buffer previously equilibrated to 37°C, and incubated 
for 5, 20 or 60 min, under conditions identical to those of 
the pre-incubation period. 
A group of experimental vessels, having a common control 
sample, was treated with dopamine (10-3M) added either alone 
or together with either of two doses of the dopamine-receptor 
blocker pimozide (10-8M or 10-6M). Pimozide at both concen-
trations was also added alone to the renal cortical prepara-
tion. Alternatively, a second group of vessels was similarly 
treated with 10-3M dopamine, but in this instance the dop-
amine-receptor agonist apomorphine (10-6M) was added to the 
slice system either alone or together with dopamine. All 
tissue samples, including controls, were also treated with 
the dopamine beta-hydroxylase inhibitor FLA-63 (10-4M) to 
prevent conversion of dopamine to norepinephrine (99) in the 
slice preparation. FLA-63, apomorphine, and pimozide, were 
added to the tissue system prior to both the pre-incubation 
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and incubation periods whereas, dopamine was added prior to 
the incubation period only. 
Dopamine (Sigma), apomorphine, and FLA-63 (Regis Chemi-
cal Co.) solutions were prepared in 0.1% ascorbic acid (Sig-
ma) to prevent oxidation. Pimozide solution (Janssen Phar-
maceutical) were prepared in 1.2% tartaric acid (Sigma) for 
the same reason. 
Following incubation, the supernatant medium was collec-
ted and stored at -20°C until assayed for renin concentra-
tion. Tissue used for cyclic &~P determination was collected 
at the end of all incubation periods and rapidly frozen on 
dry ice. The frozen tissue was then homogenized in 1 ml of 
8% trichloroacetic acid and stored at -20°c. 
A. Tissue Cyclic AMP Extraction and Measurement of its 
Content 
Frozen cyclic AMP tissue homogenates were allowed to 
thaw in an ice-water bath, followed by centrifugation at 
3100g for 10 min at 4°c. The supernatant was transferred to 
conical centrifuge tubes using disposable Pasteur pipettes 
while the protein-containing precipitate was discarded. The 
supernantant samples were then washed four times with 2 ml 
of water-saturated ether, vortexed for 10 sec at each step, 
and the ether phase aspirated and discarded. After the fi-
nal wash, the cyclic AMP-containing water phase was decante~ 
into glass vials previously placed on dry ice for rapid 
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freezing. The frozen samples were lyophilized and the fre-
eze-dried residue was stored at -20°C until assayed for cy-
clic AMP content. 
Cyclic AMP content of the freeze-dried material was 
measured by a modification of the competitive protein-binding 
assay of Gilman (100). The results were expressed as pice-
moles of cyclic AMP per mg of wet tissue. 
B. Purification of Tissue Renin 
Samples collected for determination of tissue renin con-
tent were homogenized in 1 ml of 0.9% sodium chloride (phy-
siological saline) at 4°C, and centrifuged for 15 min at 
3500g. The supernatant was dialyzed for 24 hrs at 4°C 
against an EDTA-saline buffer at pH 3.3, followed by heating 
to 32°C for one hour to denature any endogenous renin sub-
strate or angiotensinases, and then dialyzed again for 24 
hrs at 4°C against an EDTA-phosphate buffer at pH 7.5 (101). 
The purified supernatant samples were then stored at -20°c 
until assayed for renin concentration by radio-immunoassay 
of angiotensin I. 
c. Angiotensin I Generation and Measurement 
Renin concentration in both the dialyzed purified and 
the incubated supernatant samples, was indirectly measured 
by determining the rate of angiotensin I generation produced 
by endogenous renin present in our samples upon exposure to 
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exogenous substrate (angiotensinogen) obtained from 4 hr ne-
phrectomized dog plasma (102). An inhibitor of converting 
enzyme and angiotensinases was used to prevent ~~y further 
conversion of the angiotensin I generated during a one hour 
incubation period at 37°C. Briefly, both the dialyzed and 
incubated supernatant samples were allowed to thaw, vortexed 
for ten seconds and maintained at 4°C in an ice-water bath. 
Aliquots of 0.025 ml from each sample were transferred to 
test tubes at 4°c. Five drops of saturated sodium chloride, 
and o.s ml of 4 hr nephrectomized dog plasma previously 
treated with the converting and angiotensinase inhibitor, 
phenyl methyl sulfonyl flouride (PMSF, Sigma, 0.05 ml per ml 
plasma) , were added to each tube. The samples were then in-
cubated for one hour at 37°c, diluted 1:2 with distilled-de-
ionized water, vortexed, and then placed in a boiling water 
bath for 3 min to stop further generation of angiotensin I. 
The samples were allowed to cool and then stored at -20°C 
until assayed. 
Renin concentration in all samples was then determined 
by radio~unoassay of angiotensin I in the generated samples 
(New England Nuclear). The results were expressed as nano-
grams of angiotensin I generated per mg of wet tissue per 
hour. 
Statistical significance of the data was evaluated by 
Student's paired and unpaired t-tests and Linear Regression 
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Analysis using a programmable desk-top calculator (Hewlett-
Packard). 
RESULTS 
Resting renin release rate and tissue cyclic AMP con-
tent of renal cortical slices from sodium deficient rats 
were initially evaluated in relation to the length of incu-
bation time (Fig. 1}. Renin release rate from these con-
trol tissue samples was linear with time of incubation (p < 
0.0005}, which would be expected of metabolically active en-
docrine tissue. In contrast, cyclic AMP content was maximal 
by 20 min of incubation and then decreased to a level similar 
to that seen at 5 min by the end of a one hour incubation 
period. 
Renin release and tissue cyclic AMP content responses 
to 10-3M dopamine administration were subsequently examined 
and compared to those of non-treated control samples (Fig. 2). 
These data show that the mean renin release rate of the dop-
amine-treated samples appeared to be higher than that of 
controls at 5 min and 20 min, and was significantly greater 
by 60 min. Similarly, corresponding tissue cyclic AMP levels 
were significantly greater than those of controls as early 
as 5 min. Tissue renin levels in dopamine-treated samples 
were not different from those of controls at 60 min. 
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To further evaluate the type of mechanism mediating the 
stimulatory effect of dopamine on renin release, an experi-
ment was designed to examine the effect of the dopamine-re-
ceptor agonist apomorphine, added alone or together with 
dopamine, on renin secretion, tissue cyclic AMP content, and 
tissue renin content (Fig. 3). In the presence of 10-6M apo-
morphine, dopamine was no longer capable of stimulating ren-
in release or tissue cyclic AMP content levels in our corti-
cal preparation. Apomorphine by itself did not affect renin 
release but it did stimulate cyclic AMP content at 60 min. 
Mean tissue renin content changes in the presence of dopamine 
plus apomorphine were consistent with those seen in renin 
release and cyclic AMP content. 
An additional study was undertaken to provide further 
evidence regarding the mechanism by which the dopamine-recep-
tor blocker pimozide stimulates renin secretion as previously 
reported (1,2). In this study, the effect of pimozide alone 
or together with dopamine, on renin release, tissue cyclic 
AMP content, and tissue renin content was examined in rela-
tion to the time of incubation (Fig. 4). The data show that 
two doses of pimozide (10-8M and 10-6M) added to the tissue 
preparation, caused a significant increase in renin release 
coupled with a significant decrease in tissue cyclic AMP 
content during a one hour incubation period. These changes 
were seen whether dopamine was present or not, suggesting 
the the effect was due to pimozide itself. In addition, the 
26 
mean tissue renin content appeared decreased by the a~~ini­
stration of pimozide when compared to controls. When the 
renin release, tissue renin content, and tissue cyclic AMP 
content responses to both pimozide doses were evaluated in 
regard to time of incubation (Fig. 5), the significant sti-
mulatory effect of this agent on renin release and its simul-
taneous marked inhibition of cyclic AMP content were evident 
as 5 min of incubation. At 60 min, mean tissue renin content 
of pimozide-treated samples appeared to be lower than that 
of controls. Furthermore, the renin release and tissue ren-
in content changes caused by pimozide administration appear-
ed dose-dependent, whereas those seen in tissue cyclic AMP 
content were similar in magnitude regardless of the dose 
used. 
Fig. 6 depicts the results of our study with dopamine 
and apomorphine, and those generated in a parallel study uti-
lizing the dopamine-receptor blocker d-butaclamol and the 
phosphodiesterase inhibitor theophylline. The implication 
of the significant stimulation of renin release and tissue 
cyclic AMP content seen in the presence of dopamine, theo-
phylline or d-butaclamol, and the corresponding inhibition 
of the stimulatory effect of dopamine on these parameters 
caused by apomorphine administration is discussed in the 
next section. 
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Figure 1 
> 
. Resting renin release rate and tissue cyclic &~P levels 
in renal cortical slices from sodium deficient rats. The 
data represent the mean renin release rate ± S.E. of 14 - 32 
observations and the mean tissue cyclic k~P level ± S.E. of 
12 - 14 observations at 3 incubation times. The mean rest-
ing renin release rate at S, 20, and 60 min of incubation 
was 2.55 ~ 0.28ng/mg/hr, 3.86 ± o.80ng/mg/hr, and 10.28 ± 
l.Olng/mg/hr, respectively. The corresponding mean resting 
tissue cyclic AMP levels were, 0.397 ± 0.032~nol/mg, 0.616 ± 
0.076pmol/mg, and 0.436 ± 0.046pmol/mg, respectively. The 
DBH inhibition FLA-63 (10-4M) was added to all samples u~ 
this and subsequent experiments. 
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Figure 2 
Renin release rate, tissue cyclic AMP content, and tis-
sue renin content responses to 10-3 M dopamine added to renal 
cortical slices from sodium deficient rats. The data repre-
sent the mean renin release rate ± S.E. of 14 - 32 observa-
tions, the mean tissue cyclic AMP content ± S.E. of 12 - 14 
observations, and the mean tissue renin content ± S.E. of 23 
observations at 3 incubation times. The mean control (un-
treated} renin release rate and tissue cyclic AMP content 
values are the same as those described in Fig. 1. Mean con-
trol tissue renin content at 60 min was 1419 ± 103ng/mg/hr. 
RENIN 
RELEASE 
lng/mg/hr I 
c-AMP 
CONTENT 
I pmollmg I 
20 
12 
8 
4 
0 
1.2-
.8 
.4 
0 
DCOtHROL 
IJf]ooPAMINE 1o-3M 
• 
.. 
5 
., 
.... 
·.·.·.·.· 
:-:-:.:-· 
20 
ll significantly different from 
control (p<O.OS) 
lllli afgnificantly different from 
control (p<O.Ol) 
!>It 
.. 
.. 
.. 
.. 
... 
.. 
... 
.. 
... 
... 
... 
... 
.... 
.... 
.... 
.. 
.. 
.... 
.. 
* 
~-------60--------~ 
·TIME (MIN) 
'· 
30 
2000 
1600 
1200 TISSUE 
RENt;,; 
CONTENT 
800 
[ng /mg/hrJ 
,100 
0 
31 
LEGEND 
Figure 3 
Changes in renin release, tissue cyclic AMP content, 
and tissue renin content, in response to 10-3M dopamine and 
-6 . 10 M apomorph~ne, added separately or together to renal 
cortical slices from sodium deficient rats. The data repre-
sent the mean renin release change ± S.E. of 7 - 15 observa-
tions, the mean tissue cyclic AMP content change ± S.E. of 
7 - 8 0bservations, and the mean tissue renin content change 
± S.E. of 24 observations for each treatment at 3 incubaticn 
times. The mean control (untreated) renin release rate at 
5, 20, and 60 min of incubation was 2.56 ± 0.48ng/mg/hr, 
4.69 ± 1.5lng/mg/hr, and 10.60 ± 1.39ng/rng/hr, respectively. 
The corresponding mean control cyclic AMP content values 
were, respectively, 0.39 ± 0.033pmol/rng, 0.527 ± 0.094pmol/ 
mg, and 0.453 ± 0.072pmol/mg. Mean control tissue renin 
content at 60 min was 489ng/mg/hr. 
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Figure 4 
Renin release, tissue cyclic AMP content, and tissue 
renin content responses to 10-3M dopamine, added along or 
together with 10-8M or l0-6H pimozide to renal cortical 
slices from sodium deficient rats. The data represent the 
mean renin release rate ± S.E. of 11 observations, the mean 
tissue cyclic AMP content ± S.E. of 9 observations, and the 
mean tissue renin content ± S.E. of 11 observations, for 
each treatment during a 60 min incubation period. The mean 
control (non-treated) renin release rate was 14.2 ± 3.6lng/ 
mg/hr, mean control cyclic.~ content was 0.794 ± O.l94pmol/ 
mg, and mean control tissue renin content was 3833 ± 866ng/ 
mg/hr, respectively. 
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Figure 5 
Changes in renin release, tissue cyclic &~ content, 
and tissue renin content, in response to two doses of pimo-
zide added separately to a renal cortical slice preparation 
from sodium deficient rats. The data represent the mean ren-
in release change ± s.E. of 11 observations, the mean tissue 
c~clic ~~W content change ± S.E. of 6 - 9 observations, and 
the mean tissue renin content change ± S.E. of 11 observa-
tions for each treatment at 3 incubation times. The mean 
control (non-treated) renin release rate at s, 20, and 60 
min of incubation was 3.38 ± 0.88ng/mg/hr, 8.84 ± l.97ng/mg/ 
hr, and 14.2 ± 3.6lng/mg/hr, respectively. The correspond-
ing mean control cyclic &~P content values were, respective-
ly, 0.767 ± O.l76pmol/mg, 1.14 ± 0.33pmol/mg, and 0.794 ± 
O.l94pmol/mg. Mean control tissue renin content at 60 min 
was 3833 ± 866ng/mg/hr. 
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Figure 6 
Changes in renin release, tissue 'cyclic AMP content, 
and tissue renin content in response to 10-3M dopamine added 
alone or together with 10-3M theophylline, 10-6M d-butacla-
mol, or 10-6M apomorphine, to renal cortical slices from so-
diurJ deficient rats. The data represent the mean renin re-
lease ch~'ge ± s.E. of 2 - 18 observations, the mean tissue 
cyclic AMP content change ± S.E. of 2 - 12 observations, and 
the mean tissue renin content change ± S.E. of 9 - 24 obser-
vations for each treatment at 3 incubation times. The mem1 
control (non-treated) values for treatments involving dop-
amine alone or together with theophylline and d-butaclamol 
at 5, 20, and 60 min o~ incubation were, respectively, 2.55 
± 0.276, 3.86 ± 0.801, and 10.28 ± l.Olng/mg/hr for,renin 
release1 0.397 ± 0.032, 0.616 ± 0.076, and 0.437 ± 0.046 
pmol/mg for cyclic &~ content; and 1419 ± 303ng/mg/hr for 
tissue renin content at 60 min. The corresponding mean con-
tr.ol values for treatments involving dopamine alone or to-
gether with apomorphine in regard to the same 3 parameters 
at s, 20, and 60 min, are the the same as those described in 
Figure 3. 
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DISCUSSION 
The use of an in vitro renal cortical slice system in 
this study allowed an effective evaluation not only of the 
effect of isolated stimuli on renin release, but also of the 
dynamics of renin secretion in resting tissue in relation to 
time. Investigators utilizing this type of renal prepara-
tion have demonstrated that in resting renal tissue (11,103), 
renin secretion is an active process which is linear with 
time. The data generated in the present study, utilizing 
the sodium deficient rat (Fig. 1), clearly support this view. 
Dopamine has been shown to stimulate in vitro renin se-
cretion by a beta-adrenergic receptor mechanism (1,2,3,4) 
mediated by tissue cyclic AMP changes (1,2). Our data sup-
ports these observations by demonstrating that the signifi-
cant stimulatory effects exerted by dopamine on renin re-
lease after one hour of incubation (Fig. 2), was preceded by 
a significant increase in tissue cyclic AMP content as early 
as 5 min of incubation. This view is further supported by 
data from a parallel study in our laboratory (12), which 
show that addition of the phosphodiesterase inhibitor, theo-
phylline, to our cortical preparation, significantly poten-
39 
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tiates the renin release and tissue cyclic AMP content re-
sponses to dopamine (Fig. 6). 
Although the mean tissue renin content of our dopamine-
treated samples was not significantly different from that of 
controls (Fig. 2), it was greater in magnitude, suggesting 
the possibility of renin synthesis in response to dopamine 
administration. Data from parallel studies utilizing_ theo-
phylline (Fig. 6) are consistent with this possibility since 
the mean tissue renin content responses to dopamine admini-
stration were potentiated when theophylline was simultaneous-
ly added to our in vitro system. This agrees with a number 
-
of previous studies reporting that catecholamine administra-
tion stimulates renin synthesis as well as renin secretion. 
For instance, addition of norepinephrine or epinephrine has 
been reported to increase tissue renin content in renal pre-
parations from cats (73) and that this effect is prevented 
by administration of the protein inhibitor, cyclohexamide. 
The use of radioactively labeled amino acids in monitoring 
:.new renin synthesis in response to sympathetic stimuli, has 
recently confirmed these findings (104). 
The concept of a specific renal dopaminergic receptor 
mediating the stimulatory effect pre-
viously proposed (105,106). The results of our study utili-
zing the dopamine-receptor agonist, apomorphine (Fig. 3), 
do not agree with this view. Instead, they suggest that dop-
amine may exert an inhibitory effect on renin release via 
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a cyclic AMP-mediated--dopamine-specific receptor mechanism, 
as indicated by the fact that apomorphine prevented the stim-
ulatory effect of dopamine on renin release and tissue cyclic 
AMP content. The observation in a parallel study (Fig. 6) on 
the potentiation of dopamine-induced renin release by the dop-
amine-receptor blocker, d-butaclamol, offers further support 
for the concept of dopamine-receptor mediated inhibition of 
renin release. Thus, our data suggest that dopamine may exert 
a dual regulatory control on renin secretion, namely a stimu-
latory one through a beta-adrenergic receptor mechanism and 
an inhibitory one via a dopamine-receptor pathway. This is 
not surprising, since dopamine has been reported to have the 
molecular flexibility required to effectively bind to struc-
turally different receptors (107). However, the physiologic-
al significance of this dual regulation of renin secretion by 
dopamine is unclear. A similar type of control has been pre-
viously proposed in regard to the effect of norepinepherine 
on renin secretion (9,10,74,75). Recently, Quesada et. al. 
(4), have reported results similar to those seen in our study, 
although the significance of the potentiation of renin release 
observed upon administration of the dopamine-receptor blocker, 
haloperidol, was not discussed. In hibitory effects by dop- -
amine, which appear to be mediated by dopamine-specific recep-
tors, have also been demonstrated in regard to aldosterone 
(108), episodic luteinizing hormone (109) , and prolactin re-
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lease ( 112) • 
Data from the present study (Fig. 4) confirm previous 
in vitro observations in our laboratory (1,2) in regard to 
the significant effect exerted by the dopamine-receptor 
blocker, pimozide, on renin release and tissue cyclic AMP 
content during a one our incubation period. The significant 
stimulatory effect on renin release and the simultaneous de-
pression of cyclic AMP content caused by the administration 
of this agent in previous studies, was confirmed in this 
study utilizing two additional doses. Furthermore, this 
dissociation of the renin release and tissue cyclic AMP re-
sponses to pimozide administration, occurred whether or not 
dopamine was s~ultaneously added, suggesting that the effect 
was due to pimozide itself. Our results (Fig. 4) have ex-
tended our previous observations by showing that tissue renin 
content at 60 min appeared decreased in relation to controls, 
suggesting an inhibition of de novo synthesis. The results 
--
of a subsequent experiment (Fig. 5), which examined the ef-
fects of pimozide on renin release, cyclic AMP content, and 
tissue renin content in relation to time, suggest that the 
action of this agent on these parameters is not mediated by 
a physiological mechanism, but rather by a toxic effect exert-
ed on the membrane of the renin-secreting cells. This view 
is supported by our observation that the rate of renin re-
lease in response to pimozide was markedly increased as early 
as 5 min, suggesting that pre-formed renin was being prefer-
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entially released, perhaps due to the alterations in juxta-
glomerular cell membrane permeability. Furthermore, the de-
creased levels in tissue cyclic AMP and tissue renin content 
seen in our study, are consistent with the view that pharma-
cological toxicity will inactivate membrane-bound adenylate 
cyclase systems. Pharmacological changes in membrane struc-
ture and permeability leading to uncontrolled renin release, 
have also been postulated to be important in the stimulatory 
effect exerted by the beta-receptor agonist isoproterenol 
(66), perhaps involving changes in tissue cyclic AMP and tis-
sue renin content similar to those seen in our study. This 
possibility however, cannot be confirmed, since these inves-
tigators only evaluated changes in renin release. In view 
of reports (95) questioning the specificity of pimoiide as a 
dopamine receptor blocker in peripheral organ systems, it is 
clear that specific dopamine-receptor antagonists need to be 
used in order to effectively evaluate the possibility that 
dopamine receptors participate in the regulation of renin 
secretion from the mammalian kidney. 
In summary, the data reported in this paper support the 
concept that dopamine may regulate renin secretion by two 
distinct receptor mechanisms involving changes in tissue cy-
clic AMP levels. Activation of beta-adrenergic receptors 
mediates its stimulatory effect (2) , while its inhibitory 
action may be exerted through dopamine-specific receptors 
(12). Additionally, these results clearly suggest that pim-
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ozide-stimulated renin release may be the consequence of 
adenyl cyclase inactivation induced by a generalized toxic 
effect exerted by pimozide on the juxtaglomerular cell mem-
brane, leading to alterations in its permeability. 
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